ClinVar Miner

Submissions for variant NM_000517.6(HBA2):c.389T>C (p.Leu130Pro)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003486522 SCV004240927 pathogenic alpha Thalassemia 2023-12-12 criteria provided, single submitter clinical testing Variant summary: HBA2 c.389T>C (p.Leu130Pro), also known as Hb Utrecht, results in a non-conservative amino acid change located in the Globin (IPR000971) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 248988 control chromosomes. c.389T>C has been reported in the literature in multiple individuals from a large family affected with Alpha Thalassemia (example, Harteveld_1996). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in absence of HBA protein by SDS-PAGE in RBC cells (Wajcman_2011). The following publications have been ascertained in the context of this evaluation (PMID: 8790146, 21950764). No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.